San Francisco

Researchers are evaluating a new, affordable way to monitor people with multiple sclerosis MS using patient-recorded selfie videos. This study aims to see if videos collected remotely on a mobile phone can provide the same walking and speech information as traditional in-person visits. The goal is to create a low-burden, patient-centered method that can be used widely and easily by diverse people with MS. Participants will record five short selfie videos at home during baseline, 3 months, 6 months, and 12 months. They will also attend in-person visits at baseline, 6 months, and 12 months for additional data collection. These videos capture daily activities like walking and talking, using the participants own device such as a smartphone, tablet, or computer without special software. During the study, participants will undergo several assessments including video uploads and in-person evaluations lasting about 15 minutes for video collection and one hour for in-person visits. Researchers will measure how well video data matches standard MS functional tests, the usability of the video method, and its ability to detect subtle changes over time. The study lasts one year and aims to improve remote monitoring for people living with MS.

This research aims to evaluate a web-based decision support tool designed to help men make informed choices about vasectomy and other birth control options. The study focuses on understanding whether the decision aid improves users knowledge about vasectomy, reduces decisional conflict, and influences interest in vasectomy compared to men who do not use the tool. The trial is randomized and compares two groups to assess these outcomes. Participants are randomly assigned to either use the Vasectomy Right for Me web-based decision aid or to complete a survey without using the decision aid. Those in the decision aid arm engage with the tool to learn about vasectomy and alternative contraception methods before answering survey questions. The control group completes the survey directly after randomization without access to the decision aid. During the study, participants will complete surveys assessing their knowledge about vasectomy, their decisional conflict regarding contraceptive choices, and their interest in vasectomy. These assessments occur up to 45 minutes after the assigned intervention or survey completion. The study is sponsored by the University of Pittsburgh and aims to better understand factors that influence mens reproductive decisions related to vasectomy.

Researchers are evaluating the performance of PathFinder 1.0 software in detecting retinal abnormalities using OCT B-scans from CIRRUS 6000 and 5000 imaging systems. The study aims to measure the sensitivity and specificity of this diagnostic tool in adults with and without various macular abnormalities affecting the central macula. Participants will undergo standard OCT imaging on CIRRUS HD-OCT systems. The PathFinder 1.0 software will analyze these images to identify macular abnormalities such as vitreoretinal interface disruption, hyporeflective spaces within or beneath the retina, ellipsoid zone disruption, and retinal pigment epithelium changes. This is a device study with two groups subjects with no macular abnormalities and subjects with specific retinal changes. The software analysis does not affect clinical care. Participants will attend a single study visit for OCT image acquisition. The study will assess the softwares ability to correctly identify abnormalities by calculating sensitivity, specificity, positive and negative predictive values, rate of acceptable scans, and algorithm repeatability. Participants must be able to complete ophthalmic imaging and comply with study instructions. The total participation involves just this baseline imaging visit with no treatment intervention or follow-up required.

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Researchers are evaluating the safety and effects of combining a targeted radionuclide therapy called 177Lu-PSMA-617 with liver-directed treatments in men who have metastatic castration-resistant prostate cancer mCRPC with liver metastases. This phase 1b open-label study focuses on patients whose cancer has progressed despite prior androgen pathway inhibitor treatments. The study aims to understand how well this combined approach controls disease and its safety profile using standard response criteria. Participants receive up to six cycles of 177Lu-PSMA-617 intravenously every 6 weeks. Those with PSMA-negative liver lesions receive a single session of liver-directed therapy such as transarterial chemoembolization TACE or ablation before starting the radionuclide treatment. If liver disease remains stable or progresses after two cycles, additional liver-directed therapy may be given. Treatment continues until disease progression, unacceptable side effects, or study completion. During the study, participants undergo imaging tests like PETCT scans, tumor biopsies, and complete questionnaires to assess responses. Researchers monitor safety through adverse event reports and measure outcomes such as objective response rates, progression-free survival, overall survival, and prostate-specific antigen PSA declines. Follow-up visits occur every 3 months for up to 5 years after the last treatment to track long-term effects.

This research aims to evaluate the use of 18F-Fluoro-L-DOPA PET imaging as a pre-operative tool to distinguish between focal and diffuse forms of congenital hyperinsulinism HI and to locate focal lesions in the pancreas. Congenital hyperinsulinism is a common cause of persistent low blood sugar in infants, often requiring surgery when medications do not work. Identifying focal lesions before surgery could help guide pancreatic resection more accurately. The study involves imaging patients diagnosed with congenital hyperinsulinism using 18F-Fluoro Dopa PET scans. This imaging technique is being assessed for its ability to detect and locate diseased areas in the pancreas. The trial is a single-arm phase 2 study where all participants receive the 18F-Fluoro Dopa imaging. Participants must stop certain medications before the scan to ensure accurate imaging results. Participants will undergo the PET scan, and researchers will measure the sensitivity and accuracy of the imaging within four weeks. Additional semi-quantitative assessments will also be performed. The study includes infants and children up to 18 years old, with careful monitoring of liver and kidney function. The total time for outcome measurement is four weeks after imaging to evaluate its diagnostic performance.

Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.

Researchers are evaluating the use of XYOSTED as a testosterone replacement therapy in adolescent males aged 12 to under 18 years with primary or secondary hypogonadism, a condition where the body produces little or no testosterone. This Phase 34 open-label study aims to assess how well XYOSTED supports the continuation or start of puberty, along with its safety and the testosterone levels it maintains. Participants will receive XYOSTED injections at doses tailored to their weight and targeted pubertal stage. Dose adjustments will be made based on testosterone levels measured at specific intervals after dosing, with evaluations approximately every three months to reach the desired hormone levels. After completing the 52-week initial study period, participants may enter a 24-month extension to further monitor long-term safety and treatment effects. Throughout the study and extension, participants will undergo clinical examinations including pubertal staging, blood tests for testosterone and other labs, bone density scans, body composition assessments, and X-rays to monitor bone age. Researchers will track changes in puberty progression, bone health, body measurements, and hormone levels. Participants will attend regular clinic visits every six months during the extension phase to continue safety and pharmacokinetic evaluations.

Researchers are evaluating the use of a radiotracer called 64Cu-GRIP B with PET imaging to detect granzyme B, a biomarker produced by immune cells during immunotherapy, in patients with advanced cancers that have spread to nearby tissues or lymph nodes. This phase III study focuses on genitourinary cancers, including renal cell carcinoma, urothelial cancer, and metastatic castration-resistant prostate cancer, aiming to assess safety and usefulness of the imaging in monitoring immune response. Participants are divided into four groups based on cancer type metastatic genitourinary malignancies, renal cell and urothelial carcinoma, metastatic castration-resistant prostate cancer, and other solid tumors. All receive the 64Cu-GRIP B injection followed by PET scans at baseline. Some groups have additional scans at 8 weeks and at disease progression. Imaging methods include PETCT or PETMRI, with safety monitoring conducted at multiple time points after tracer injection. During the study, patients undergo scans, blood sampling, and tumor biopsies when applicable. Researchers monitor adverse events, tracer distribution, and tumor uptake patterns over time. Outcomes measured include safety, tracer pharmacokinetics, changes in tumor uptake values, and correlations with clinical outcomes such as response to immunotherapy and progression-free survival. Participants are followed for up to two years to assess long-term effects and disease progression.

Researchers are working to create and use a comprehensive database focused on intracranial aneurysms IA. This project collects and studies clinical history, imaging data, biological samples, and other information to understand factors linked to the formation and rupture of aneurysms. They aim to identify genetic, environmental, and anatomical markers, as well as evaluate outcomes from different treatment strategies and improve patient care protocols. Participants include patients with diagnosed aneurysms, both ruptured and unruptured, family members of affected individuals, and healthy volunteers. Data collected involves detailed clinical records, imaging scans like MRI angiography and CT angiography, and various biological samples such as blood, cerebrospinal fluid, saliva, and stool. Consent covers access to medical records, use of biological samples, and potential future research uses including genetic analyses. During the study, participants provide health and lifestyle information, imaging data, and biological samples. Researchers will monitor multiple long-term outcomes including disease progression, life expectancy, quality of life, neurological and cognitive status, and treatment effects over periods up to 20 years. Data confidentiality is maintained, and participants can withdraw at any time without affecting their medical care. The study aims to validate disease models and support advances in aneurysm management and research.